Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High Following Analyst Upgrade

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) hit a new 52-week high during trading on Thursday after HC Wainwright raised their price target on the stock from $48.00 to $56.00. HC Wainwright currently has a buy rating on the stock. Enliven Therapeutics traded as high as $36.72 and last traded at $35.53, with a volume of 6419955 shares trading hands. The stock had previously closed at $31.15.

A number of other research analysts have also recently issued reports on ELVN. Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Mizuho upped their target price on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Enliven Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $43.40.

Insiders Place Their Bets

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of Enliven Therapeutics stock in a transaction on Friday, February 6th. The stock was sold at an average price of $29.04, for a total value of $145,200.00. Following the completion of the transaction, the insider owned 740,188 shares in the company, valued at approximately $21,495,059.52. The trade was a 0.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Benjamin Hohl sold 10,000 shares of the business’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $29.58, for a total value of $295,800.00. Following the completion of the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 232,180 shares of company stock valued at $6,217,033. Company insiders own 25.90% of the company’s stock.

Trending Headlines about Enliven Therapeutics

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target to $56 and maintained a Buy rating, implying sizable upside versus recent levels — a clear catalyst for investor demand. HC Wainwright raises PT to $56 (Benzinga)
• Positive Sentiment: Mizuho boosted its target to $45 and set an Outperform rating, reinforcing the analyst upgrade momentum and providing additional institutional validation. Mizuho raises PT to $45 (Benzinga)
• Positive Sentiment: Merck’s $6.7B acquisition of Terns lifted sentiment across the oncology group and directly benefited Enliven by highlighting the value of blood-cancer programs, which helped spark a large intraday jump in ELVN shares. Merck buys Terns — ELVN share reaction (MSN)
• Positive Sentiment: Coverage notes that ELVN has hit new multi‑year and 52‑week highs as analysts turn upbeat, which can attract momentum and crossover buying from funds tracking breakouts. ELVN hits 52-week high (American Banking News)
• Neutral Sentiment: Several media outlets and aggregator posts are amplifying the price-target changes and deal-driven optimism; this increases visibility but doesn’t change fundamentals immediately. Coverage roundup (Kalkine Media)

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP bought a new position in shares of Enliven Therapeutics in the fourth quarter worth about $180,000. Invesco Ltd. grew its stake in shares of Enliven Therapeutics by 7.0% during the fourth quarter. Invesco Ltd. now owns 24,720 shares of the company’s stock valued at $381,000 after purchasing an additional 1,624 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Enliven Therapeutics by 472.6% during the fourth quarter. XTX Topco Ltd now owns 60,702 shares of the company’s stock valued at $935,000 after purchasing an additional 50,101 shares during the last quarter. Vestal Point Capital LP increased its holdings in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after purchasing an additional 2,670,000 shares in the last quarter. Finally, Virtus Investment Advisers LLC increased its holdings in shares of Enliven Therapeutics by 172.6% in the fourth quarter. Virtus Investment Advisers LLC now owns 15,778 shares of the company’s stock valued at $243,000 after purchasing an additional 9,991 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

The firm’s 50-day moving average is $28.32 and its two-hundred day moving average is $22.84. The stock has a market cap of $2.35 billion, a P/E ratio of -21.12 and a beta of 0.33.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). As a group, research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.